Newswire (Published: Friday, November 17, 2017, Received: Thursday, November 9, 2017, 6:01:03 PM CST)

Word Count: 520

Research from Peking University Yields New Findings on Prostate Cancer (Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news originating from Beijing, People's Republic of China, by NewsRx correspondents, research stated, "In this work, a semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model to quantitatively describe the antitumor activity of docetaxel (Doc) and cabozantinib (Cab) under monotherapy, concurrent therapy, interval therapy and different sequential therapy in mouse xenograft models of castration-resistant prostate cancer (CRPC) was developed and evaluated. Pharmacokinetics of Doc and Cab when administered separately and simultaneously were investigated in nude mice, and pharmacodynamic study was conducted in tumor-bearing mice treated with different dosing schedules."

Our news journalists obtained a quote from the research from Peking University, "The PK interaction between Doc and Cab was expressed by adding the effect of Cab on the clearance of Doc in PK model. And the PD interaction between the two drugs was demonstrated by the developed PK/PD model through combination index 'ph'. Our results showed that the concurrent therapy and Doc followed by Cab (Doc ~ Cab) sequential therapy exhibited better tumor inhibitory efficacy than monotherapy. The Cab followed by Doc (Cab ~ Doc) sequential schedule was less effective than monotherapy, and the interval therapy did not enhance the anti-tumor efficacy compared with the concurrent therapy. Parameter 'ph' estimated from the PK/PD model quantitatively characterized the action between Doc and Cab. There was no significant PD interaction between Doc and Cab in both concurrent schedule and interval schedule, while the effect of the two drugs in 'Doc ~ Cab' and 'Cab ~ Doc' sequential schedule was synergistic and antagonistic, respectively."

According to the news editors, the research concluded: "The proposed model properly described the anti-tumor effects of Doc and Cab under different treatment schedules, and could be used for dose optimization through model-based simulation."

For more information on this research see: Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models. The Journal of Pharmacology and Experimental Therapeutics, 2017;(): (see also Oncology - Prostate Cancer).

The news correspondents report that additional information may be obtained from T. Zhou, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China. Additional authors for this research include R. Chen, J. Li, Y. Fu, L. Yang, H. Su, Y. Yao, L. Li, T. Zhou and W. Lu.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Asia, Antineoplastics, Biotechnology, Pharmaceuticals, Beijing, Oncology, Xenografts, Prostate Cancer, Pharmacodynamics, Pharmacokinetics, Docetaxel Therapy, Xenotransplantion, Mitotic Inhibitors, Drugs and Therapies, Prostatic Neoplasms, People's Republic of China.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Peking University


Eastern Asia
People's Republic of China


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies
            Medicinal Drugs